Will the FDA approve at least 50 new drugs in 2026?
Current probability of “Yes”: 50%
- Status
- Open
- Category
- Science
- Closing date
- 20 January 2027
- Participants
- 0
VangAI analysis
VangAI edge: +35 pp
- The current FDA 'Novel Drug Approvals for 2026' list contains 47 approvals, close to the threshold of 50.
- In the third quarter of 2026, 22 new drugs were approved, indicating a high approval rate.
- Historically, the FDA has often exceeded 50 new drug approvals annually.
- Several additional drug approvals are anticipated in the remaining two months of 2026.
Like a marathon runner who has already completed 47 kilometers out of 50, with two kilometers remaining to the finish line.
Market rules
"Yes" if, on the official FDA page "Novel Drug Approvals for 2026" (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) as of January 20, 2027, 12:00 UTC, there are 50 or more approvals listed for the 2026 calendar year. Numeric threshold: >= 50 entries (field "Showing 1 to N of N entries" / maximum number in column No.). Reference as of 08.03.2026: 29 drugs are listed, latest approvals from 07.24.2026, page updated 07.29.2026. Otherwise, "No". Edge cases: only drugs included by the FDA in this list (novel drugs CDER) are counted; approvals added to the page after January 20, 2027, are not counted, even if the approval date relates to 2026; exactly 50 — "Yes"; subsequent removal of an entry from the list does not change the outcome. If the page is temporarily unavailable or updated with delay, the result is fixed based on the same page within 72 hours after the resolution date.